Antoine Verger1,2,3, Gabriele Stoffels1, Norbert Galldiks1,4,5, Philipp Lohmann1, Antje Willuweit1, Bernd Neumaier1, Stefanie Geisler1, Karl-Josef Langen6,7,8. 1. Institute of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Jülich, 52425, Jülich, Germany. 2. Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Lorraine University, Nancy, France. 3. IADI, INSERM, UMR 947, Lorraine University, Nancy, France. 4. Department of Neurology, University Hospital Cologne, Cologne, Germany. 5. Centre of Integrated Oncology (CIO), Universities of Cologne and Bonn, Cologne, Germany. 6. Institute of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Jülich, 52425, Jülich, Germany. k.j.langen@fz-juelich.de. 7. Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany. k.j.langen@fz-juelich.de. 8. Section JARA-Brain, Jülich-Aachen Research Alliance (JARA), Jülich, Germany. k.j.langen@fz-juelich.de.
Abstract
PURPOSE: Cis-4-[18F]fluoro-D-proline (D-cis-[18F]FPro) has been shown to pass the intact blood-brain barrier and to accumulate in areas of secondary neurodegeneration and necrosis in the rat brain while uptake in experimental brain tumors is low. This pilot study explores the uptake behavior of D-cis-[18F]FPro in human brain tumors after multimodal treatment. PROCEDURES: In a prospective study, 27 patients with suspected recurrent brain tumor after treatment with surgery, radiotherapy, and/or chemotherapy (SRC) were investigated by dynamic positron emission tomography (PET) using D-cis-[18F]FPro (22 high-grade gliomas, one unspecified glioma, and 4 metastases). Furthermore, two patients with untreated lesions were included (one glioblastoma, one reactive astrogliosis). Data were compared with the results of PET using O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) which detects viable tumor tissue. Tracer distribution, mean and maximum lesion-to-brain ratios (LBRmean, LBRmax), and time-to-peak (TTP) of the time activity curve (TAC) of tracer uptake were evaluated. Final diagnosis was determined by histology (n = 9), clinical follow-up (n = 10), or by [18F]FET PET (n = 10). RESULTS: D-cis-[18F]FPro showed high uptake in both recurrent brain tumors (n = 11) and lesions classified as treatment-related changes (TRC) only (n = 16) (LBRmean 2.2 ± 0.7 and 2.1 ± 0.6, n.s.; LBRmax 3.4 ± 1.2 and 3.2 ± 1.3, n.s.). The untreated glioblastoma and the lesion showing reactive astrogliosis exhibited low D-cis-[18F]FPro uptake. Distribution of [18F]FET and D-cis-[18F]FPro uptake was discordant in 21/29 cases indicating that the uptake mechanisms are different. CONCLUSION: The high accumulation of D-cis-[18F]FPro in pretreated brain tumors and TRC supports the hypothesis that tracer uptake is related to cell death. Further studies before and after therapy are needed to assess the potential of D-cis-[18F]FPro for treatment monitoring.
PURPOSE:Cis-4-[18F]fluoro-D-proline (D-cis-[18F]FPro) has been shown to pass the intact blood-brain barrier and to accumulate in areas of secondary neurodegeneration and necrosis in the rat brain while uptake in experimental brain tumors is low. This pilot study explores the uptake behavior of D-cis-[18F]FPro in humanbrain tumors after multimodal treatment. PROCEDURES: In a prospective study, 27 patients with suspected recurrent brain tumor after treatment with surgery, radiotherapy, and/or chemotherapy (SRC) were investigated by dynamic positron emission tomography (PET) using D-cis-[18F]FPro (22 high-grade gliomas, one unspecifiedglioma, and 4 metastases). Furthermore, two patients with untreated lesions were included (one glioblastoma, one reactive astrogliosis). Data were compared with the results of PET using O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) which detects viable tumor tissue. Tracer distribution, mean and maximum lesion-to-brain ratios (LBRmean, LBRmax), and time-to-peak (TTP) of the time activity curve (TAC) of tracer uptake were evaluated. Final diagnosis was determined by histology (n = 9), clinical follow-up (n = 10), or by [18F]FET PET (n = 10). RESULTS:D-cis-[18F]FPro showed high uptake in both recurrent brain tumors (n = 11) and lesions classified as treatment-related changes (TRC) only (n = 16) (LBRmean 2.2 ± 0.7 and 2.1 ± 0.6, n.s.; LBRmax 3.4 ± 1.2 and 3.2 ± 1.3, n.s.). The untreated glioblastoma and the lesion showing reactive astrogliosis exhibited low D-cis-[18F]FPro uptake. Distribution of [18F]FET and D-cis-[18F]FPro uptake was discordant in 21/29 cases indicating that the uptake mechanisms are different. CONCLUSION: The high accumulation of D-cis-[18F]FPro in pretreated brain tumors and TRC supports the hypothesis that tracer uptake is related to cell death. Further studies before and after therapy are needed to assess the potential of D-cis-[18F]FPro for treatment monitoring.
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Matthew J Oborski; Charles M Laymon; Yongxian Qian; Frank S Lieberman; Arden D Nelson; James M Mountz Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243
Authors: Carina Stegmayr; Ulrike Bandelow; Dennis Oliveira; Philipp Lohmann; Antje Willuweit; Christian Filss; Norbert Galldiks; Joachim H R Lübke; N Jon Shah; Johannes Ermert; Karl-Josef Langen Journal: Eur J Nucl Med Mol Imaging Date: 2016-09-09 Impact factor: 9.236
Authors: Mohan Doss; Hartmuth C Kolb; Joseph C Walsh; Vani Mocharla; Hong Fan; Ashok Chaudhary; Zhihong Zhu; R Katherine Alpaugh; Miriam N Lango; Jian Q Yu Journal: J Nucl Med Date: 2013-10-17 Impact factor: 10.057
Authors: Matthew J Oborski; Charles M Laymon; Frank S Lieberman; Jan Drappatz; Ronald L Hamilton; James M Mountz Journal: Brain Behav Date: 2014-02-12 Impact factor: 2.708